-
NEJM: Nubeqa (darolutamide) significantly extends the lifespan of patients with non-metastatic prostate cancer!
Time of Update: 2020-09-23
Karim Fizazi, head of research at ARAMIS, said: "Through ongoing research, we have identified treatments that focus on extending life expectancy and reducing side effects in men with nmCRPC." men who received drarolutamide combined androgen deprivation therapy (ADT) showed significant improvement in OS compared to placebo combined ADT, and a 31% lower risk of death (HR s 0.69, 95% CI 0.53-0.88, p s 0.003).
-
Qilu Pharmaceuticals" Malay acid afatini tablets were approved for sale.
Time of Update: 2020-09-23
On September 3, Qilu Pharmaceuticals submitted a new class of 4 generic drug Malay acid afatinib tablets approved by the State Drug Administration for listing, the second domestic company after Haussen approved the product for listing.
-
NEJM: Long-term survival data for patients with Stage III melanoma treated by Dabrafenib in association with Traminib are encouraging.
Time of Update: 2020-09-23
a follow-up study of up to 5 years, Dabrafenib combined traminib therapy reduced the risk of recurrence or metastasis in patients with POST-surgery BRAFV600E or V600K mutation Stage III melanoma.
-
JCI:NK cell-assisted PD-1 is used in NSCLC, and the effect is multiplied.
Time of Update: 2020-09-23
3, tumor markers, circulating tumor cells Although the fact that Pym monotherapy was found to have some effect in Group B, the levels of cancer embryo antigen (CEA), cytochroprotein 19 antigen 21-1 (Cyfra21-1) or carbohydrate antigen 125 (CA125) in Group A were significantly reduced after the combined treatment (Figure C).
-
Gilead has committed $800 million to Jounce to create innovative cancer immunotherapy.
Time of Update: 2020-09-23
the key projects currently being developed by Jounce include monoclonal antibody JTX-2011, which stimulates induced costulent molecules, and super-T cells that disrupt target interactions on tumor-related macrophages.
JTX-1811 in this protocol is a monoclonal antibody designed to selectively remove immunosuppressive tumor-immersive regulatory T (TITR) cells.
-
Fda priority reviews applications for peptide-drug melflufen to treat refractic multiple myeloma.
Time of Update: 2020-09-23
, chief executive of Oncopeptides, said: "This is exciting news and an important step in Melflufen's treatment of patients with multiple myeloma." Melflufen (INN melphalan flufenamide) is the first peptide-drug coupled (PDC) that targets amino peptide enzymes and rapidly releases alkanes into tumor cells.
-
Authoritative interpretation! The 2020 edition of the China Oncology Clinical Practice Guide is about to be released.
Time of Update: 2020-09-23
on the afternoon of the Re-release Guide, from 14:30-16:00 on September 12, the organizers will also organize the first interpretation and expert symposium of the 2020 edition of the Clinical Practice Guide on Oncology in China in the form of live webcasts, focusing on the sharing of the core contents and highlights of the Re-edition Guide.
-
The United States approved Roche's new all-tumor liquid biopsy testing platform.
Time of Update: 2020-09-23
FoundationOne Liquid CDx is a Genomic Analysis (CGP) test that analyzes more than 300 cancer-related genes and multiple genomic characteristics to identify genetic mutations in tumors and optimize patient care.
-
Nature: The lymphatic system protects tumor cells from iron death and promotes cancer cell metastasis.
Time of Update: 2020-09-23
although some cancer cells migrate through the lymphatic tubes before they enter the bloodstream and form distant metastasis, it is not clear whether exposure to lymphatic fluid affects the subsequent survival of these cells in the blood.
-
Cell Death Differ: AQP1 may be used as an indicator for predicting the sensitivity of cycloviral drugs in breast cancer patients.
Time of Update: 2020-09-23
researchers also found that miR-320a-3p can reduce the chemotherapy sensitivity of cyclopenoids by inhibiting the expression of AQP1.
the results of the study, which showed that AQP1 could serve as a predictive indicator in chemotherapy for cyclocyctic drugs, could help improve the prognostics of breast cancer patients who are better suited to chemotherapy with cyclocyclyctic drugs (high levels of AQP1 expression).
-
Don't give up! 2020 glioblastoma is worth looking forward to the study progress inventory.
Time of Update: 2020-09-23
2, the dawn of the new dendracyte vaccine on April 8, 2020, the new dendratic cell therapy AV-GBM-1 Phase II clinical trial data released, the study showed that this new vaccine to extend the new diagnosis of glioblastoma patients in the medium-term overall survival show great potential.
-
Br J Cancer: New non-invasive exhalation test to diagnose early-stage head and neck cancer.
Time of Update: 2020-09-23
based on mass spectrometrometrometical analysis, two logic regression models were used to distinguish the respiratory status of cancer patients and 2 (benign disease) patients.
results show that non-invasive respiratory test diagnosis of HNSCC may be a potentially practical and accurate diagnostic method.
-
Estrogen-like agonist TTC-352, an anti-breast cancer drug with therapeutic potential.
Time of Update: 2020-09-23
Debra Tonetti, of the UIC School of Pharmacy, said: "Although there are many treatments for breast cancer, about half of women with ER-positive cancer are resistant to hormone therapy.
-
Antibody drug adjulycturing drug Vic-) quertoju monoantitor Duocarmazine to treat HER2-positive solid tumors: Phase I clinical studies have been initiated.
Time of Update: 2020-09-23
Byondis, a pharmaceutical company, announced today that a phase I study of a joint treatment of HER2-positive solid tumor patients with the research antibody-drug association (ADC) and synthesizer monoantigen Duocarmazine (SYD985) and Nirapali has officially begun, with the first patients already in the group.
-
Cancer Cell: More powerful! Liao Xuebin/Wei Li collaboration reveals that HPK1 can be a target for T-cell immunotherapy.
Time of Update: 2020-09-23
further demonstrated that genetic depletion, pharmacological inhibition, or protein hydrolysis of HPK1 mediated by proTAC can improve the effectiveness of CAR-T cell-based immunotherapy in various preclinical mouse models of blood and solid tumors.
-
The re-ding bioCD3/CD20 dual resistance has been approved for 5 clinical projects and is expected to raise US$1 billion for a secondary listing in Hong Kong.
Time of Update: 2020-09-23
in April this year, Reding Pharmaceuticals and Regeneration Yuan reached an agreement to obtain the exclusive commercial rights to the development and exclusive commercialization of cancer-related oncology in Chinese mainland, Hong Kong, Taiwan and Macau with a down payment of US$30 million and a registration and sales milestone payment of up to US$160 million.
-
JAMA Surg: 2014 SSO-ASTRO New guidelines for breast cancer breast surgery cut-out reduce the risk of re-surgery in patients.
Time of Update: 2020-09-23
study concluded that the rate of re-surgery in patients with early breast cancer decreased following the release of new guidelines for breast cancer preservation surgery in 2014.
-
BMJ: Radiotherapy for early breast cancer in breast-preservation surgery.
Time of Update: 2020-09-23
for early breast cancer patients who could receive breast care, the treatment effect of single radiotherapy was comparable to that of in-body radiation therapy after surgery, and the mortality rate from non-breast cancer was low.
-
J Exp Med: Lu Jianxin/Lu Zhimin team to reveal a new mechanism of glioma stethocell immune escape.
Time of Update: 2020-09-23
study found that abnormally activated AKT/beta-catenin signals in glioblastomas lead to elevated levels of expression in the immune checkpoint molecule PD-L1 and cause tumor immune escape.
-
NEJM: Conjunctival squamous cell carcinoma - case reported.
Time of Update: 2020-09-23
The patient, an 89-year-old woman, was treated in ophthalmology for 4 months due to redness in her eyes and a foreign object in her right eye.
in follow-up 2 years after surgery, there was no local recurrence.
